reports
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Eval...
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the efficacy and safety of petosemtamab, a Biclonics® targeting EGFR and LGR5, in combination with pemb...
Merus gibt Behandlung des ersten Patient in klinischer Phase-III-Studi...
Merus gibt Behandlung des ersten Patient in klinischer Phase-III-Studie LiGeR-HN1 zur Bewertung von Petosemtamab in Kombination mit Pembrolizumab bei rezidivierendem/metastasierendem Plattenepithelkarzinom des Kopfes und Halses in der Erstlinie bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein im klinischen Stadium tätiges Onkologieunternehmen, das innovative, multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass der erste...
Merus annonce que le premier patient a été traité dans le cadre de l’é...
Merus annonce que le premier patient a été traité dans le cadre de l’étude LiGeR-HN1, un essai de Phase III évaluant le pétosemtamab en association avec le pembrolizumab en traitement de première intention contre le CETC r/m UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 30 sept. 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS) (« Merus », « la Société », « nous », « notre » ou « nos »), une société du secteur de l’oncologie au stade clinique qui met au point des anticorps multispécifiques de pleine longueur innovants (Biclonics® et Triclonics®), a annoncé aujourd’hui que le premier patient a ét...
Merus gibt Annahme von Abstracts zur Präsentation auf dem ESMO Asia Co...
Merus gibt Annahme von Abstracts zur Präsentation auf dem ESMO Asia Congress 2024 bekannt Petosemtamab in 2L+ HNSCC – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute die Annahme eines Abstracts über Petosemtamab, einen Biclonics®-Antikörper, der auf EGFR und LGR5, bei...
Merus annonce l'acceptation du résumé pour présentation lors du congrè...
Merus annonce l'acceptation du résumé pour présentation lors du congrès de l’ESMO Asie 2024 Les données cliniques intermédiaires relatives au pétosemtamab dans le traitement de deuxième intention ou ultérieur (2L+) du carcinome épidermoïde de la tête et du cou (CETC) ont été sélectionnées pour une présentation orale rapide UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 18 sept. 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS) (Merus, la Société, nous, notre ou nos), une société du secteur de l’oncologie au stade clinique qui met au point des anticorps multispécifiques de pleine longueur innova...
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Co...
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024 Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of an abstract on petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients with recurrent/metastatic head a...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
PENN PENN NATIONAL GAMING INC.
PBF PBF ENERGY INC. CLASS A
MTDR MATADOR RESOURCES COMPANY
I3N CHART INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
CRWS CROWN CRAFTS INC.
CODI COMPASS DIVERSIFIED HOLDINGS
CHCT COMMUNITY HEALTHCARE TRUST INCORPORATED
BEN FRANKLIN RESOURCES INC.
RLMD RELMADA THERAPEUTICS
CULP CULP INC.
HTLD HEARTLAND EXPRESS INC.
MYRG MYR GROUP INC.
RIGN TRANSOCEAN LTD.
GBDC GOLUB CAPITAL BDC INC.
HLT HILTON WORLDWIDE HOLDINGS INC
APTV APTIV PLC
CLAR CLARUS CORPORATION
APPN APPIAN
CNX CONSOL ENERGY INC.
TALO TALOS ENERGY INC.
TCPC BLACKROCK TCP CAPITAL CORP.
ETON ETON PHARMACEUTICALS
STIM STIMSONITE CORP
ONEW ONEWATER MARINE
ADV ADVANTAGE SOLUTIONS INC (A)
GRNT GRANIT SKOPKE
FTCI FTC SOLAR
INBX INC.
TDUP INHIBRX
FTHY INC.
AMLX THREDUP INC.
CRGY FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
PFHC AMYLYX PHARMACEUTICALS INC
BTSG CRESCENT ENERGY CO
SYRS PROFRAC HLDG CORP
PEO BRIGHTSPRING HEALTH SERVICES INC.
XPER SYROS PHARMACEUTICALS INC.
PETROLEUM & RESOURCES CORPORATION
XPERI INC
- Jonathan Moreland
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
PAYC PAYCOM SOFTWARE INC.
MTDR MATADOR RESOURCES COMPANY
CRWS CROWN CRAFTS INC.
CHCT COMMUNITY HEALTHCARE TRUST INCORPORATED
TCPC BLACKROCK TCP CAPITAL CORP.
ONEW ONEWATER MARINE
ADV ADVANTAGE SOLUTIONS INC (A)
CERT CERTARA
OLO OLO
INBX INHIBRX
TDUP INC.
MRNA THREDUP INC.
MODERNA
INC.
Advantage Solutions to Participate in the Wells Fargo 7th Annual Consu...
Advantage Solutions to Participate in the Wells Fargo 7th Annual Consumer Conference ST. LOUIS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) announced today that Chris Growe, Chief Financial Officer, will meet with investors at the Wells Fargo 7th Annual Consumer Conference in Dana Point, Calif., on September 18, 2024. Contact your Wells Fargo representative for more details about attending the conference and scheduling a meeting with Advantage Solutions. About Advantage Solutions Advantage Solutions is the leading omnichannel retail solutions agency in Nort...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing...
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on September 3, 2024, the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 12,660 shares of common stock and restricted stock units (RSUs) for 6,330 shares of common stock to 3 new employees under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved th...
Adverum Biotechnologies to Participate in Upcoming Fall Investor Confe...
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10th at 3:30 p.m. ET.Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1st at 8:00 a.m. E.T.UBS V...
Advantage Solutions unveils comprehensive rebrand, emphasizing unified...
Advantage Solutions unveils comprehensive rebrand, emphasizing unified market approach The company goes to market as one cohesive brand that will enhance efficiency and effectiveness ST. LOUIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ADV) today unveiled a new brand identity inspired by its dynamic workforce and designed to reflect its transition to a unified retail solutions company positioned at the center of brands, retailers and shoppers. Advantage, a provider of sales and omnichannel marketing solutions to consumer goods manufacturers and retailers, launched its new visual ide...
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results ...
Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif.,...
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Busi...
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update - Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade serous ovarian carcinomas - - Five abstracts presented at AACR provide strong scientific rationale for the clinical development of onvansertib across multiple tumor types and various combinations - - Cash and equivalents of $60 million as of June 30, 2024, projected runway through the end of...
Advantage Solutions Reports 2024 Second Quarter Results and Reaffirms ...
Advantage Solutions Reports 2024 Second Quarter Results and Reaffirms its Full-Year Outlook Management expects 2024 revenues and Adjusted EBITDA to grow low single digits on a continuing operations basis. Actions to simplify the business are substantially complete, marking an important milestone in the Company's strategic transformation. Divestiture of non-core assets in 2024 generated proceeds of ~$280 million available to opportunistically reduce debt. ST. LOUIS, Aug. 07, 2024 (GLOBE...
Merus präsentiert auf der 44. Annual Growth Conference von Canaccord G...
Merus präsentiert auf der 44. Annual Growth Conference von Canaccord Genuity UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Dienstag, Aug. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein im klinischen Stadium tätiges Onkologieunternehmen, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, auf der 44. Annual Growth Conference von Canaccord Genuity am Dienstag, 13. August 2024, von 9:00-9:25 Uhr ET einen Vortrag halten wird. Der Webcast...
Merus fera une présentation lors de la 44e conférence annuelle sur la ...
Merus fera une présentation lors de la 44e conférence annuelle sur la croissance de Canaccord Genuity UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 06 août 2024 (GLOBE NEWSWIRE) -- . (Nasdaq : MRUS), une société d’oncologie au stade clinique développant des anticorps de pleine longueur multispécifiques et novateurs (Biclonics® et Triclonics®), a annoncé ce jour que Bill Lundberg, M.D., Président et directeur général de Merus, fera une présentation lors de la 44e conférence annuelle sur la croissance de Canaccord Genuity le mardi 13 août 2024, de 9 h à 9 h 25 (heure de l’Est). Le webcast...
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Canaccord Genuity’s 44th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET. The webcast of the presentation will be contemporaneously available on the of the Company's w...
Advantage Solutions Receives Amazon’s Inaugural Gold Tier Award, Refle...
Advantage Solutions Receives Amazon’s Inaugural Gold Tier Award, Reflecting Excellence in Omnicommerce Performance Award affirms Advantage’s role as a market leader in comprehensive e-commerce solutions, with full-service Amazon capabilities to drive exceptional growth for brands ST. LOUIS, Aug. 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ADV), a leading provider of sales and marketing services to consumer goods manufacturers and retailers, announced today it has been named one of the first companies to win Amazon’s inaugural Gold Tier award. Amazon’s Gold Tier award recognizes direct fulfi...
Merus annonce ses résultats financiers pour le deuxième trimestre 2024...
Merus annonce ses résultats financiers pour le deuxième trimestre 2024 et fait le point sur ses activités - Données provisoires de l’association pétosemtamab + pembrolizumab présentées lors de l’édition 2024 du congrès de l’ASCO®, avec démonstration d’un taux de réponse solide de 67 % chez 24 patients évaluables. – Premiers patients traités dans le cadre d’un essai de phase III évaluant le pétosemtamab en monothérapie dans le traitement du CETC en 2e/3e ligne, d’un essai de phase II évaluant le pétosemtamab en association avec une chimiothérapie standard dans le traitement du CCRm en 2e li...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.